Cargando…
Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
BACKGROUND: Immune checkpoint inhibitors (ICIs) have significant clinical efficacy in the treatment of non‐small cell lung cancer (NSCLC); however, the incidence of immune‐related adverse events (irAEs) of up to 50% has prevented their widespread use. With the increase in the use of ICIs alone or as...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471041/ https://www.ncbi.nlm.nih.gov/pubmed/32643323 http://dx.doi.org/10.1111/1759-7714.13541 |